Compound: Nalorphine
SMILES: O1c2c(O)ccc3c2[C@@]45[C@@H]1[C@@H](O)C=C[C@H]4[C@H](N(CC=C)CC5)C3
InChIKey: UIQMVEYFGZJHCZ-SSTWWWIQSA-N
Synonyms: Nalorphine, N-Allylnormorphine, Nalorfina, Allylnormorphine, 62-67-9, Nalorphinum, Nalorphine serb, Normorphine, N-allyl-, N-Allyl-N-desmethylmorphine, U59WB2WRY2, NANM, N-Allyl-7,8-dehydro-4,5-epoxy-3,6-dihydroxymorphinan, DTXSID3023348, Morphinan-3,6-alpha-diol, 17-allyl-7,8-didehydro-4,5-alpha-epoxy-, Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-(2-propenyl)-, (5alpha,6alpha)-, (-)-Nalorphine, (1S,5R,13R,14S,17R)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo(9.6.1.0^(1,13).0^(5,17).0^(7,18))octadeca-7(18),8,10,15-tetraene-10,14-diol, (1S,5R,13R,14S,17R)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol, (4R,4aR,7S,7aR,12bS)-3-allyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro(3,2-e)isoquinoline-7,9-diol, (4R,4aR,7S,7aR,12bS)-3-allyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol, (4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro(3,2-e)isoquinoline-7,9-diol, (4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol, Hydrobromide, Nalorphine, Hydrochloride, Nalorphine, RefChem:164455, DTXCID303348, V03AB02, 200-546-1, Allorphine, Nalorphinium, Anthorphine, Antorfin, Antorphin, Antorphine, Nalorphin, Anarcon, Norfin, Nallin, Acetorfin, CHEBI:7458, Nalorphine (INN), DEA No. 9400, NALORPHINE [INN], Acetorfin [Czech], Nalorfina [DCIT], Nalorphine [INN:BAN], Nalorphinum [INN-Latin], HSDB 3278, NCGC00168255-01, EINECS 200-546-1, UNII-U59WB2WRY2, N-allyl-normorphine, NALORPHINE [MI], 7,8-Didehydro-4,5-epoxy-17-(2-propenyl)morphinan-3,6-diol, NALORPHINE [HSDB], NALORPHINE [MART.], NALORPHINE [WHO-DD], Epitope ID:2281333, SCHEMBL38920, CHEMBL415284, GTPL1629, BDBM50367061, PDSP2_001572, DB11490, NS00008614, D08247, Q2622916, (5alpha,6alpha)-17-prop-2-en-1-yl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol, 17-(Prop-2-en-1-yl)-5alpha-7,8-didehydro-4,5-epoxymorphinan-3,6alpha-diol, MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-(2-PROPENYL)-(5.ALPHA.,6.ALPHA.)-
Theoretical properties:
molecular_formula: C19H21NO3
molecular_weight: 311.4 g/mol
exact_mass: 311.15214353 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 2
heavy_atom_count: 23
topological_polar_surface_area: 52.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals (from diethyl ether)
color: Crystals (from diethyl ether)
melting_point: 208 °C
solubility: ODORLESS; WHITE OR PRACTICALLY WHITE, CRYSTALLINE POWDER; INSOL IN CHLOROFORM & ETHER; SOL IN DIL ALKALI HYDROXIDE /NALORPHINE HYDROCHLORIDE/
Descriptions:
pubchem: Nalorphine is a morphinane alkaloid.
chembl: NALORPHINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Nalorphine (INNTooltip International Nonproprietary Name; also known as N-allylnormorphine; brand names Lethidrone and Nalline) is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence.
Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.